Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
Christopher Nelke(University of Münster), Tobias Ruck(University Hospital Münster), Niklas Huntemann(University Hospital Münster), Sven G. Meuth(University of Würzburg), Saskia Räuber(University of Münster), Frauke Stascheit(Humboldt-Universität zu Berlin), Stefan Tenzer(German Cancer Research Center), Andreas Roos(University of Duisburg-Essen), Andreas Meisel(Charité - Universitätsmedizin Berlin), Alice Willison(Düsseldorf University Hospital), Nico Melzer(University of Würzburg), Kai Stühler(Heinrich Heine University Düsseldorf), Ute Distler(Johannes Gutenberg University Mainz), Marc Pawlitzki(University Hospital Münster), Christina B. Schroeter(University of Münster)
Cited by 10
Related Papers
Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism
|Cell|2020|627
Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use
|The Lancet Neurology|2009|581
Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model.
|PubMed|2002|452
Erythropoietin Is a Paracrine Mediator of Ischemic Tolerance in the Brain: Evidence from an<i>In Vitro</i>Model
|Journal of Neuroscience|2002|387